Ranbaxy Internal Audit Disclosure Highlights U.S. FDA Policy Exceptions

Ranbaxy's uphill battle to keep U.S. FDA from seeing a consultant's audit reports provides a sobering reminder of the circumstances under which the agency will seek to review such documents - and the pressure it can exert on a company to release them